Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

L. Khoja; E. G. Atenafu; S. Suciu; S. Leyvraz; T. Sato; E. Marshall; U. Keilholz; L. Zimmer; S. P. Patel; S. Piperno-Neumann; J. Piulats; T. T. Kivela; C. Pfoehler; S. Bhatia; P. Huppert; L. B. J. Van Iersel; I. J. M. De Vries; N. Penel; T. Vogl; T. Cheng; G. Fiorentini; F. Mouriaux; A. Tarhini; P. M. Patel; R. Carvajal; A. M. Joshua

doi:10.1093/annonc/mdz176

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

L. Khoja, E. G. Atenafu, S. Suciu, S. Leyvraz, T. Sato, E. Marshall, U. Keilholz, L. Zimmer, S. P. Patel, S. Piperno-Neumann, J. Piulats, T. T. Kivela, C. Pfoehler, S. Bhatia, P. Huppert, L. B. J. Van Iersel, I. J. M. De Vries, N. Penel, T. Vogl, T. ChengG. Fiorentini, F. Mouriaux, A. Tarhini, P. M. Patel, R. Carvajal, A. M. Joshua^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.

Methods: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.

Results: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus = 3 cm versus

Conclusion: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.

Original language	English
Pages (from-to)	1370-1380
Number of pages	11
Journal	Annals of Oncology
Volume	30
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdz176
Publication status	Published - Aug 2019

Keywords

meta-analysis
uveal melanoma
trial design
survival benchmarks
STAGE-IV MELANOMA
PHASE-II TRIAL
GEMCITABINE PLUS TREOSULFAN
LIVER METASTASES
CHEMOEMBOLIZATION TACE
CHOROIDAL MELANOMA
1ST-LINE TREATMENT
INTRAARTERIAL
TEMOZOLOMIDE
COMBINATION

Access to Document

10.1093/annonc/mdz176Licence: Free access - publisher

Cite this

Khoja, L., Atenafu, E. G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S. P., Piperno-Neumann, S., Piulats, J., Kivela, T. T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L. B. J., De Vries, I. J. M., Penel, N., Vogl, T., ... Joshua, A. M. (2019). Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Annals of Oncology, 30(8), 1370-1380. https://doi.org/10.1093/annonc/mdz176

@article{97b3c7beb89f4729b8f8390c8aeaf58f,

title = "Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study",

abstract = "Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.Methods: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.Results: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus = 3 cm versusConclusion: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.",

keywords = "meta-analysis, uveal melanoma, trial design, survival benchmarks, STAGE-IV MELANOMA, PHASE-II TRIAL, GEMCITABINE PLUS TREOSULFAN, LIVER METASTASES, CHEMOEMBOLIZATION TACE, CHOROIDAL MELANOMA, 1ST-LINE TREATMENT, INTRAARTERIAL, TEMOZOLOMIDE, COMBINATION",

author = "L. Khoja and Atenafu, {E. G.} and S. Suciu and S. Leyvraz and T. Sato and E. Marshall and U. Keilholz and L. Zimmer and Patel, {S. P.} and S. Piperno-Neumann and J. Piulats and Kivela, {T. T.} and C. Pfoehler and S. Bhatia and P. Huppert and {Van Iersel}, {L. B. J.} and {De Vries}, {I. J. M.} and N. Penel and T. Vogl and T. Cheng and G. Fiorentini and F. Mouriaux and A. Tarhini and Patel, {P. M.} and R. Carvajal and Joshua, {A. M.}",

year = "2019",

month = aug,

doi = "10.1093/annonc/mdz176",

language = "English",

volume = "30",

pages = "1370--1380",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

Khoja, L, Atenafu, EG, Suciu, S, Leyvraz, S, Sato, T, Marshall, E, Keilholz, U, Zimmer, L, Patel, SP, Piperno-Neumann, S, Piulats, J, Kivela, TT, Pfoehler, C, Bhatia, S, Huppert, P, Van Iersel, LBJ, De Vries, IJM, Penel, N, Vogl, T, Cheng, T, Fiorentini, G, Mouriaux, F, Tarhini, A, Patel, PM, Carvajal, R & Joshua, AM 2019, 'Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study', Annals of Oncology, vol. 30, no. 8, pp. 1370-1380. https://doi.org/10.1093/annonc/mdz176

TY - JOUR

T1 - Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks

T2 - an international rare cancers initiative (IRCI) ocular melanoma study

AU - Khoja, L.

AU - Atenafu, E. G.

AU - Suciu, S.

AU - Leyvraz, S.

AU - Sato, T.

AU - Marshall, E.

AU - Keilholz, U.

AU - Zimmer, L.

AU - Patel, S. P.

AU - Piperno-Neumann, S.

AU - Piulats, J.

AU - Kivela, T. T.

AU - Pfoehler, C.

AU - Bhatia, S.

AU - Huppert, P.

AU - Van Iersel, L. B. J.

AU - De Vries, I. J. M.

AU - Penel, N.

AU - Vogl, T.

AU - Cheng, T.

AU - Fiorentini, G.

AU - Mouriaux, F.

AU - Tarhini, A.

AU - Patel, P. M.

AU - Carvajal, R.

AU - Joshua, A. M.

PY - 2019/8

Y1 - 2019/8

N2 - Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.Methods: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.Results: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus = 3 cm versusConclusion: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.

AB - Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.Methods: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.Results: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus = 3 cm versusConclusion: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.

KW - meta-analysis

KW - uveal melanoma

KW - trial design

KW - survival benchmarks

KW - STAGE-IV MELANOMA

KW - PHASE-II TRIAL

KW - GEMCITABINE PLUS TREOSULFAN

KW - LIVER METASTASES

KW - CHEMOEMBOLIZATION TACE

KW - CHOROIDAL MELANOMA

KW - 1ST-LINE TREATMENT

KW - INTRAARTERIAL

KW - TEMOZOLOMIDE

KW - COMBINATION

U2 - 10.1093/annonc/mdz176

DO - 10.1093/annonc/mdz176

M3 - Article

SN - 0923-7534

VL - 30

SP - 1370

EP - 1380

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

Abstract

Keywords

Access to Document

Fingerprint

Cite this